Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

The primary objective of this study is to evaluate the safety and tolerability of
subcutaneously (SC) administered multiple, escalating doses of BG00011 (a humanized
monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin, formerly known as
STX-100) in participants with IPF. The Secondary objectives are to estimate the
pharmacokinetic (PK) parameters after the 1st dose and after the last dose of multiple,
escalating doses of BG00011 in participants with IPF, to assess the immunogenicity of BG00011
in participants with IPF, and to assess the effect of BG00011 on biomarkers isolated from
bronchoalveolar lavage (BAL) and peripheral blood in participants with IPF.